Dapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury

Dapagliflozin, a new type of drug used to treat diabetes mellitus (DM), is a sodium/glucose cotransporter 2 (SGLT2) inhibitor. Although some studies showed that SGLT2 inhibition attenuated reactive oxygen generation in diabetic kidney the role of SGLT2 inhibition is unknown. We evaluated whether SLT...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Yoon-Kyung, Choi, Hyunsu, Jeong, Jin Young, Na, Ki-Ryang, Lee, Kang Wook, Lim, Beom Jin, Choi, Dae Eun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4938401/
https://www.ncbi.nlm.nih.gov/pubmed/27391020
http://dx.doi.org/10.1371/journal.pone.0158810

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4938401/
https://www.ncbi.nlm.nih.gov/pubmed/27391020
http://dx.doi.org/10.1371/journal.pone.0158810

Ejemplares similares